Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “High Risk NMIBC”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT07646145
What this trial is testing

Disitamab Vedotin Plus Intravesical Mitomycin C in HER2-Expressing Intermediate- to High-Risk Non-Muscle-Invasive Bladder Cancer

Who this might be right for
Non-Muscle-Invasive Bladder Cancer (NMIBC)
Shanxi Province Cancer Hospital 30
Large-scale testing (Phase 3)WithdrawnNCT07551544
What this trial is testing

ANKTIVA Plus BCG Versus BCG Monotherapy In Participants With BCG-Naïve/BCG-Exposed High-Grade Non-Muscle Invasive Papillary Bladder Cancer

Who this might be right for
NMIBC
ImmunityBio, Inc.
Not applicableLooking for participantsNCT06889623
What this trial is testing

Immediate Chemotherapy Following Resection for High-Risk Non-Muscle-Invasive Bladder Cancer

Who this might be right for
NMIBC
Changhai Hospital 72
Large-scale testing (Phase 3)UnknownNCT06241755
What this trial is testing

Clinical Trial for Evaluating the Efficacy and Safety of BCG for Therapeutic Use in the Prevention of Postoperative Recurrence of Medium/High-risk Non-muscle Invasive Bladder Cancer (NMIBC)

Who this might be right for
Non-Muscle Invasive Bladder Cancer
Chengdu CoenBiotech Co., Ltd 412
Large-scale testing (Phase 3)Active Not RecruitingNCT03711032
What this trial is testing

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)

Who this might be right for
High-risk Non-muscle Invasive Bladder Cancer
Merck Sharp & Dohme LLC 1,397
Not applicableLooking for participantsNCT07784387
What this trial is testing

Characterize High-Risk Non-Muscle-Invasive Bladder Cancer Participants in Portugal

Who this might be right for
Urinary Bladder Neoplasms
Janssen-Cilag Farmaceutica Ltda. 250
Early research (Phase 1)Study completedNCT03053635
What this trial is testing

Intravesical Photodynamic Therapy (PDT) in BCG Refractory High-Risk Non-muscle Invasive Bladder Cancer (NMIBC) Patients

Who this might be right for
Non-Muscle Invasive Bladder Cancer (NMIBC) Refractory to BCG
Theralase® Technologies Inc. 6
Not applicableLooking for participantsNCT06287541
What this trial is testing

The Necessity of a Second Transurethral Resection in High-risk Non-muscle-invasive Bladder Cancer Patients With Negative Urine Biomarker After Initial Transurethral Resection

Who this might be right for
Non Muscle Invasive Bladder Cancer
The First Affiliated Hospital with Nanjing Medical University 428
Not applicableUnknownNCT05671900
What this trial is testing

Gemcitabine and Docetaxel Therapy in High-risk BCG-naive Patients With Non-muscle Invasive Bladder Cancer

Who this might be right for
Non-muscle-invasive Bladder Cancer
Clinical Hospital Centre Zagreb 70
Not applicableNot Yet RecruitingNCT06982690
What this trial is testing

Anesthesia Modality and Oncologic Outcomes in High-Risk NMIBC: A Randomized Trial

Who this might be right for
NMIBCTURBTBladder (Urothelial, Transitional Cell) Cancer+3 more
National Taiwan University Hospital 370
Not applicableLooking for participantsNCT07130578
What this trial is testing

The Guiding Value of Liquid Biopsy Based on Urinary Tumor DNA/RNA in the Second Transurethral Resection of High-risk Non-muscle Invasive Bladder Cancer

Who this might be right for
Bladder CancerLiquid Biopsy
Tianjin Medical University Second Hospital 60
Post-approval studies (Phase 4)Active Not RecruitingNCT04701151
What this trial is testing

NORTH-REG Dwell-Time Study

Who this might be right for
Side Effect of Drug
Jørgen Bjerggaard Jensen 314
Testing effectiveness (Phase 2)Looking for participantsNCT06972615
What this trial is testing

Intravesical Chemotherapy in Combination With Systemic Pembrolizumab in NMIBC Unresponsive or Exposed to BCG Therapy

Who this might be right for
Non Muscle Invasive Bladder Cancer
BLATAM 37
Large-scale testing (Phase 3)Looking for participantsNCT07000084
What this trial is testing

Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy

Who this might be right for
Recurrent Non-Muscle Invasive Bladder CarcinomaStage 0a Bladder Cancer AJCC v8Stage I Bladder Cancer AJCC v8
Alliance for Clinical Trials in Oncology 330
Testing effectiveness (Phase 2)Active Not RecruitingNCT04179162
What this trial is testing

Bacillus Calmette-Guérin (BCG) and Gemcitabine in People With High-Grade Non-Muscle Invasive Bladder Cancer That Came Back After BCG Treatment

Who this might be right for
Non-Muscle Invasive Bladder Cancer (NMIBC)
Memorial Sloan Kettering Cancer Center 54
Not applicableLooking for participantsNCT07763197
What this trial is testing

Sample Collection for Ongoing Research and Product Evaluation Study - Non-muscle Invasive Bladder Cancer (SCORE-NMIBC)

Who this might be right for
Non-Muscle Invasive Bladder CancerNMIBCHigh-risk Non-Muscle Invasive Bladder Cancer
Natera, Inc. 400
Large-scale testing (Phase 3)Looking for participantsNCT05037279
What this trial is testing

Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC)

Who this might be right for
Bladder CancerBladder Cancer RecurrentNeoplasm Recurrence+3 more
Verity Pharmaceuticals Inc. 540
Large-scale testing (Phase 3)Active Not RecruitingNCT03528694
What this trial is testing

Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer

Who this might be right for
Non-muscle-invasive Bladder Cancer
AstraZeneca 1,018
Testing effectiveness (Phase 2)Looking for participantsNCT06388720
What this trial is testing

The Clinical Effectiveness and Safety of Intravesical Mitomycin-C and Gemcitabine Sequential Therapy

Who this might be right for
Bladder Cancer
National Cancer Center, Korea 82
Testing effectiveness (Phase 2)Looking for participantsNCT05410730
What this trial is testing

SHR-1501 Alone or in Combination With BCG or SHR-1316 in Subjects With NMIBC

Who this might be right for
High-risk NMIBC
Shanghai Hengrui Pharmaceutical Co., Ltd. 150
Next Page